Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with PD according to UKPDSBB criteria (male or female).~* Patient with a Hoehn and Yahr Stage \<3 in the ON condition.~* Patients aged from 40 to 75 years old.~* Early-stage PD patients: diagnosis of PD for less than 3 years, without dyskinesia and motor fluctuations.~* Patients treated with an optimized stable dopaminergic medication regimen (dopamine agonist and/or L-dopa and/or MAOB inhibitor) for at least 1 month before baseline.~* Patients expected to remain on stable doses of antiparkinsonian medications for at least the first 6 months of the study and preferably for the 12 months of follow-up.~* Patients (or caregiver) able to self-administer lixisenatide injection.~* Patients with health insurance.~* Patients who signed the written informed consent form.~Exclusion Criteria:~* Patients suffering from other parkinsonian syndromes other than PD.~* Patients expected not to be able to remain on stable doses of symptomatic antiparkinsonian medications for at least 6-month.~* Patients with a Body Mass Index \< 18.5~* Patients suffering from type 1 or type 2 diabetes.~* Malnutrition as assessed clinically by the investigator or any sub-investigator and by Mini Nutritional Assessment Short Form (MNA-SF) score \<12 (the judgement of the investigator prevails over questionnaire scores).~* Weight change of more than 5 kg in body weight during the last 3 months prior to screening.~* Known history of drug or alcohol abuse within 6 months prior to the time of screening.~* Patients with hyperthyroidism or uncontrolled hypothyroidism. Note: Patients diagnosed with hypothyroidism need to be on a stable thyroid replacement therapy for at least 6 weeks.~* Patients with severe depression according to DSM criteria.~* Patients with cognitive impairment (MoCA score \<26).~* Severe gastrointestinal disease (e.g. gastroparesis).~* Patients previously exposed to a GLP-1 agonist.~* Patients with severely impaired renal function (estimated creatinine clearance \<30ml/min).~* Patients with a medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C (assessed by medical history), primary biliary cirrhosis, or ongoing symptomatic gallbladder disease.~* Patients with any clinically significant ECG abnormality.~* Laboratory findings at the time of screening:~Amylase and/or lipase: \>3 times the upper limit of the normal (ULN) laboratory range ALT or AST: \>3 times ULN Total bilirubin: \>1.5 times ULN (except in case of Gilbert's syndrome) Calcitonin: \>20 pg/mL (5.9 pmol/L) Hemoglobin: \<11 g/dL (male/female) and/or neutrophils \<1,500/mm3 and/or platelets \<100,000/mm3 Triglyceride (TG): \>600 mg/dL (6.78 mmol/L). History of unexplained pancreatitis, chronic pancreatitis or pancreatectomy.~* Personal or immediate family history of medullary thyroid cancer or genetic conditions that predispose to medullary thyroid cancer (e.g. multiple endocrine neoplasia syndromes).~* Hyperlipidemia.~* Females who are pregnant, breast feeding or of child bearing age without effective contraception.~* Patients treated per os in the evening by drugs requiring a rapid action (at the discretion of the investigator).~* Participants who lack the capacity to give informed consent.~* Any medical or psychiatric condition which may compromise participation in the study or the safety, at the discretion of the investigator.~* Known abnormality on CT or MRI brain imaging that is considered likely to compromise compliance with any aspect of the trial.~* Prior intra-cerebral surgical intervention for PD.~* Participant under legal guardianship or incapacitation.~* Patients who are participating or have participated in another interventional clinical trial within 30 days prior to baseline.~* Previous enrolment in the present trial.~* Allergic reaction to the active substance or to any of the excipients of lixisenatide

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lixisenatide (Type: EXPERIMENTAL): Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: once daily subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete